Kadono Y, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kamijima T, Seto C, Takano A, Yotsuyanagi S, Nakagawa R, Miyagi T, Aoyama S, Asahi H, Fukuda R, Mizokami A. Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST. Urol J [Internet]. 2021 Dec. 20 [cited 2024 Apr. 27];19(03):202-8. Available from: https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/6652